SavedAdd your journal

Journals / Journal of Clinical Research in Pediatric Endocrinology / 2018 / Cilt: 10 - Sayı: 2

A Study of the Relationship Between Cystatin C and Metabolic Bone Disease in Preterm Infants

Sabriye KORKUT
Şeyma MEMUR
Hülya HALİS
Osman BAŞTUĞ
LEVENT KORKMAZ
Ahmet ÖZDEMİR
TAMER GÜNEŞ
MEHMET ADNAN ÖZTÜRK
Selim KURTOĞLU
Pages
119–124
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The presence of OP does not affect the safety of CysC as a marker of renal insufficiency in preterm infants.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Cystatin C (CysC) is commonly used as a marker of renal failure in premature infants.
📊
Key Findings & Data:Methods: Subjects were 50 preterm infants (≤32 gestational weeks).
💡
Conclusion & Impact:Conclusion: The presence of OP does not affect the safety of CysC as a marker of renal insufficiency in preterm infants.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Cystatin C (CysC) is commonly used as a marker of renal failure in premature infants. The aim of this study was to investigate serum CysC levels in osteopenia of prematurity (OP) and determine whether CysC could be safely used as a marker of renal insufficiency in infants with OP. Methods: Subjects were 50 preterm infants (≤32 gestational weeks). Calcium (Ca), phosphorus (P) and alkaline phosphatase (ALP) serum levels were measured in postnatal week nine, and bone density was measured concurrently by quantitative ultrasonography. Patients with a Z score of <-2 were considered to have OP. Results: The mean serum CysC levels in preterm infants in postnatal week nine were 1.50±0.19 mg/L. Serum CysC levels were not correlated with speed of sound values, Z scores, serum Ca, P or ALP levels. Serum CysC levels were not significantly different between infants with OP [1.50 (1.35-1.61) mg/L] and in infants without OP [1.58 (1.28-1.70) mg/L]. Conclusion: The presence of OP does not affect the safety of CysC as a marker of renal insufficiency in preterm infants.

🔖

Cite This Article

KORKUT, S., MEMUR, Ş., HALİS, H., BAŞTUĞ, O., KORKMAZ, L., ÖZDEMİR, A., GÜNEŞ, T., ÖZTÜRK, M. A., KURTOĞLU, S. (2018). A Study of the Relationship Between Cystatin C and Metabolic Bone Disease in Preterm Infants. Journal of Clinical Research in Pediatric Endocrinology, Cilt: 10 - Sayı: 2, 119–124. https://ajindex.com/articles/202525

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Harrison CM, Gibson AT. Osteopenia in preterm infants. Arch Dis Child Fetal Neonatal Ed 2013;98:272-275. Epub 2012 May 3 Foldes AJ, Rimon A, Keinan DD, Popovetzer MM. Quantitative ultrasound of the tibia: a novel approach for assessment of bone status. Bone 1995;17:363-367.
  2. Jaworski M, Lebiedowski M, Lorenc RS, Trempe J. Ultrasound bone measurements in pediatric subject. Calcif Tissue Int 1995;56:368-371. Wüster C, de Terlizzi F, Becker S, Cadossi M, Cadossi R, Müller R. Usefulness of quantitative ultrasound in evaluating structural and mechanical properties of bone: comparison of ultrasound, dual-energy X-ray absorptiometry, micro-computed tomography, and mechanical testing of human phalanges in vitro. Technol Health Care 2005;13:497-510.
  3. Pereda L, Ashmeade T, Zaritt J, Carver JD. The use of quantitative ultrasound in assessing bone status in newborn preterm infants. J Perinatol 2003;23:655-659.
  4. Roggero P, Gianni ML, Orsi A, Piemontese P, Amato O, Mora Y, Puricelli V, Mosca F. Postnatal “Speed of Sound” decline in preterm infants: An exploratory study. J Pediatr Gastroenterol Nutr 2007;45:615-617.
  5. Altuncu E, Akman I, Yurdakul Z, Ozdoğan T, Solakoğlu M, Selim N, Bilgen H, Ozek E, Bereket A. Quantitative ultrasound and biochemical parameters for the assessment of osteopenia in preterm infants. J Maternal Fetal Neonatal Med 2007;20:401-405.
  6. Hamil K, Liu Q, Sivashanmugam P, Yenugu S, Saundararajan R, Grossman G, Richardson RT, Zhang YL, O’Rand MG, Petrusz P, French FS, Hall SH. Cystatin 11: a new member of the cystatin type 2 family. Endocrinology 2002;143:2787-2796.
  7. Bökenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C serum concentration underestimate glomerular filtration rate in renal transplant recipients. Clin Chem 1999;45:1866-1868.
  8. Mussap M, Ruzzante N, Varagnolo M, Plebani M. Quantitative automated particle-enhanced immunonepholometric assay for the routinary measurement of human cystatin C. Clin Chem Lab Med 1998;36:859-865.
  9. Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martínez-Brú C, Grubb A. Cystatin C as a marker of GFR- history, indications and future research. Clin Biochem 2005;38:1-8.
  10. Mares J, Stejskal D, Vavrouskova J, Urbanek K, Herzig R, Hlustik P. Use of cystatin C determination in clinical diagnostics. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003;147:177-180.
  11. Ensrud KE, Parimi N, Cauley JA, Ishani A, Slinin Y, Hillier TA, Taylor BC, Steffes M, Cummings SR; Study of Osteoporotic Fractures (SOF) Group.